A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Study summary

The main objective of this study is to evaluate the long-term safety of CP-690,550 in patients being treated for moderate to severe chronic plaque psoriasis. This is an open label extension study available to patients who participated in one of the qualifying studies with CP-690,550 providing entry criteria is met.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedCP-690,550 and CP-690,550

The study team can explain what participation involves.

Who it may be forMET

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jun 26, 2017 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 3

Interventional

Where is it offered?323 U.S. locations

Locations may change over time.

Who runs it?Pfizer

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 3
Sponsor: Pfizer
Interventions being studied: Drug: CP-690,550; Drug: CP-690,550

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Biomarkers

MET→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Have participated in qualifying study with CP-690,550 and are 18 years or older with diagnosis of plaque-type psoriasis (psoriasis vulgaris).

Reasons someone may not be able to joinExclusion criteria

Non-plaque or drug induced forms of psoriasis;
Cannot discontinue current oral, injectable or topical therapy for psoriasis or cannot discontinue phototherapy (PUVA or UVB).
Any uncontrolled significant medical condition.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Radiant Research, Inc.Birmingham, Alabama
UAB DermatologyBirmingham, Alabama
Horizon Research Group, Inc.Mobile, Alabama
Radiant Research, Inc.Tucson, Arizona
Burke Pharmaceutical ResearchHot Springs, Arkansas
Bakersfield Dermatology and Skin Cancer Medical GroupBakersfield, California
Associates In Research, Inc.Fresno, California
University of California IrvineIrvine, California
Dermatology Research AssociatesLos Angeles, California
Dermatology Specialists, Inc.Oceanside, California
MedDerm AssociatesSan Diego, California
UCSD DermatologySan Diego, California

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 26, 2017. Always confirm current availability with the study team.

View original record ↗